Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Empyrean Energy reports on 'frustrating year'

(Sharecast News) - Shares in Empyrean Energy dropped on Monday after the Australia-based oil and gas explorer reported its results following a "very frustrating year". The company, which is pre-revenue, reported an operating loss of $0.93m for the year to 31 March, down from a $1.22m loss the previous year, while the year-end cash balance improved to $1.68m from $0.98m.

Empyrean, which holds an 8.5% interest in the Duyung project offshore Indonesia, said a "protracted waiting period" had weighed on its financial year as it looks to maximise value from the Mako gas field within Duyung. However, recent developments "have been somewhat more encouraging", said chair John Laycock.

During the period, Empyrean acquired an option to participate in the Wilson River oil prospect in Queensland, Australia, which spudded in mid-March. It also owns a stake in the Sacramento Basin in California, though no work was conducted on the project during the period.

Just last week, Empyrean reported on the untimely death of its managing director and chief executive Tom Kelly following a tragic accident.

"For now, on behalf of the Board and all at Empyrean, I reiterate our earlier sentiments that our thoughts are with Tom's family and friends and our deepest condolences go out to them," Laycock said.

Shares were down 14.4% at 0.063p in afternoon trade, having fallen 30% so far this year.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.